NeOnc Technologies secures FDA Type B meeting to discuss accelerated approval for NEO100
NeOnc Technologies Holdings Inc. announced that the U.S. FDA has scheduled a Type B End‑of‑Phase meeting for early January 2027 to consider an accelerated approval pathway for its intranasal therapy NEO100 in recurrent or progressive IDH‑mutant grade 4 astrocytoma. The agency will review data from the completed Phase 2a portion of the NEO100‑01 trial, which showed a six‑month progression‑free survival rate of 48.9% versus a 20% benchmark and a median overall survival of 26.1 months. NeOnc also plans to discuss the design of a multicenter, randomized Phase 3 confirmatory trial that will use overall survival as the primary endpoint.
Why it matters
The meeting is a regulatory milestone that could lead to an accelerated approval, allowing the drug to reach patients sooner if the FDA is satisfied with the data. Successful approval would also trigger the start of a registrational Phase 3 trial, impacting NeOnc’s future revenue potential and clinical development timeline.
Key facts
- 1The FDA granted a Type B End‑of‑Phase meeting scheduled for early January 2027 to discuss accelerated approval for NEO100. investing.com
- 2Phase 2a results showed a six‑month progression‑free survival rate of 48.9%, exceeding the protocol‑defined benchmark of 20%. investing.com
- 3Median overall survival reported from the Phase 2a portion was 26.1 months. investing.com
- 4NeOnc will seek FDA feedback on a potential 505(b)(2) New Drug Application for accelerated approval. investing.com
- 5The planned Phase 3 trial (NEO100‑012) will compare intranasal NEO100 with standard‑of‑care chemotherapy and use overall survival as the primary endpoint. stocktwits.com
- 6NEO100 holds Fast Track and Orphan Drug designations from the FDA. investing.com
Summary written by AlphAI AI Desk from 4 of 4 sources. Not investment advice. Figures are as stated by the linked sources.